Publication Name	World Journal of Pharmacology
Manuscript ID	41201
Country	United Kingdom

Received	2018-07-27 12:51
Peer-Review Started	2018-07-29 10:52
To Make the First Decision	2018-08-31 00:30
Return for Revision	2018-09-03 02:22
Revised	2018-09-05 21:14
Second Decision	2018-09-29 08:40
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2018-10-13 02:02
Articles in Press	2018-10-13 02:02
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2018-10-20 09:00
Publish the Manuscript Online	2018-10-22 09:50

ISSN	2220-3192 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Pharmacology & Pharmacy
Manuscript Type	Editorial
Article Title	Kv7 channels a potential therapeutic target in fibromyalgia: A hypothesis
Manuscript Source	Invited Manuscript
All Author List	Kim Lawson
Funding Agency and Grant Number
Corresponding Author	Kim Lawson, PhD, Senior Lecturer, Department of Biosciences and Chemistry, Biomolecular Sciences Research Centre, Sheffield Hallam University, City Campus, Howard Street, Sheffield S1 1WB, United Kingdom. k.lawson@shu.ac.uk
Key Words	Fibromyalgia; Persistent pain; Potassium channels; Kv7 channels; Flupirtine; Retigabine
Core Tip	Fibromyalgia a multifaceted disorder remains a major unmet condition with current therapies providing limited control. An involvement of potassium channels in the pathophysiology of fibromyalgia and the related symptoms is emerging, and Kv7 channel activators, such as flupirtine and retigabine, exhibit pharmacological profiles compatible with the requirements of therapeutic approaches to fibromyalgia. Focused clinical trials with flupirtine and retigabine will provide important insight to the role of potassium channels and the utility of Kv7 channel activators in fibromyalgia.
Publish Date	2018-10-22 09:50
Citation	Lawson K. Kv7 channels a potential therapeutic target in fibromyalgia: A hypothesis. World J Pharmacol 2018; 7(1): 1-9
URL	http://www.wjgnet.com/2220-3192/full/v7/i1/1.htm
DOI	http://dx.doi.org/10.5497/wjp.v7.i1.1

Full Article (PDF)	WJP-7-1.pdf
Full Article (Word)	WJP-7-1.doc
Manuscript File	41201-Review.docx
Answering Reviewers	41201-Answering reviewers.pdf
Audio Core Tip	41201-Audio core tip.wav
Conflict-of-Interest Disclosure Form	41201-Conflict-of-interest statement.pdf
Copyright License Agreement	41201-Copyright assignment.pdf
Peer-review Report	41201-Peer-review(s).pdf
Scientific Misconduct Check	41201-Scientific misconduct check.pdf
Scientific Editor Work List	41201-Scientific editor work list.pdf